MD Anderson Symptom Inventory brain tumor module [Neurosurgery Wiki]

This page is read only. You can view the source, but not change it. Ask your administrator if you think this is wrong.
=====MD Anderson Symptom Inventory brain tumor module=====

The MD Anderson Symptom Inventory [[brain tumor]] module (MDASI-BT) is a site-specific MDASI module. Along with the core MDASI’s 13 [[symptom]] items and 6 interference items, the MDASI-BT also assesses 9 symptoms specific to brain tumors: 

[[weakness]] on one side of the body
    
difficulty understanding
    
difficulty speaking
    
seizures
    
difficulty concentrating
    
problems with vision
    
change in appearance
    
change in bowel pattern (diarrhea or constipation)
    
irritability
----
The purposes of a study were to identify and compare symptom clusters in patients with meningioma and glioma, and to assess and compare predictors of [[quality of life]] (QoL) in both patient groups.

Data were collected using the MD Anderson Symptom Inventory Brain Tumour Module, the Functional Assessment of Cancer Therapy-General, and the [[Karnofsky Performance Scale]] (KPS). Of the 158 participating patients, 77 had meningioma and 81 had glioma.

Four symptom clusters were identified with 55.4% total variance in patients with meningioma. These clusters were 1) physical, 2) cognitive, 3) elimination-appearance, and 4) motor-sensory symptoms. In patients with glioma, four clusters with a total variance of 67.3% were identified: 1) treatment-related, 2) cognitive, 3) appearance-elimination, and 4) gastrointestinal symptoms. Predictors of QoL were KPS score (β = 0.41, p < .001), cognitive symptom cluster (β = -0.36, p < .001), and physical symptom cluster (β = -0.32, p = .001) in patients with meningioma whereas treatment-related symptom cluster (β = -0.55, p < .001) was identified as the predictor of QoL in patients with glioma.

This study demonstrates that the type and composition of symptom clusters differed between patients with meningioma and glioma. In addition,  data provide evidence that even when the participants reported mild symptoms, these clusters could be used to predict QoL in patients with meningioma and glioma
((Kim SR, Shin YS, Kim JH, Choi M, Yoo SH. Differences in type composition of
symptom clusters as predictors of quality of life between patients with
meningioma and glioma. World Neurosurg. 2016 Oct 26. pii: S1878-8750(16)31074-9. 
doi: 10.1016/j.wneu.2016.10.085. [Epub ahead of print] PubMed PMID: 27794512.
)).